9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consultation with FDA
-New methodology enables a more capital-efficient study, with reduction in participants from 630 to 525 while maintaining statistical powering at...